BioAdaptives, Inc.

BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements. It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute for humans; Canine Regen and Equine Regen for dogs and horses, as well as base formulations, including Equine All-in-One to trainers, horse owners and boarding stables; and All-in-One products, which combine minerals, vitamins, amino acids, and other botanicals with the Regen compounds. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.

BioAdaptives, Inc. trades as BDPT on OTC. The company is classified in Consumer Defensive / Packaged Foods and reports in USD.

The current profile places the business in Packaged Foods. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $18,278 of revenue and -$1.56M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

BioAdaptives, Inc. can be compared against peers such as AJ1G, Inc., Blue Star Foods Corp., Dewmar International BMC, Inc., Demand Brands, Inc., Hill Street Beverage Company Inc., Komo Plant Based Foods Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $65,709, beta of 1.32, and return on equity of +73.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BDPT currently shows total debt of $384,428 and beta of 1.32. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 4 (2026-06-03 00:00:00), 10-Q (2026-05-15 00:00:00), 4 (2026-05-05 00:00:00), 10-K (2026-04-14 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.shopbioadaptives.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.